Senate plans Tuesday healthcare vote—but doesn’t know what bill will be considered

Senate Republican leaders are pushing for a July 25 vote on some form of legislation to repeal the Affordable Care Act, but haven’t decided on what will be in the bill.

The 50 votes need to pass a bill haven’t materialized on either the Republicans’ ACA replacement, the Better Care Reconciliation Act, or a revived strategy to repeal the ACA and give themselves two years to craft an alternative. The BCRA would cause 22 million more people to be uninsured by 2026 and raise an individual’s deductibles for benchmark plans to $13,000, while repeal-and-delay would grow the number of uninsured by 32 million, according to the Congressional Budget Office.

When asked if senators would know in advance what they’d voting on Tuesday, Sen. John Cornyn, R-Texas, said, “That’s a luxury we don’t have,” according to the Associated Press.

In an effort to win over skeptical Republicans, leaders are floating several proposals to add new funds to the bill, like letting states use Medicaid funds to help people buy their own private health insurance.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup